BIOMAT Database Logo BIOMAT Database Logo

Clinical efficacy of sitafloxacin 100 mg twice daily for 7 days for patients with non-gonococcal urethritis. 2013

Satoshi Takahashi, and Ryoichi Hamasuna, and Mitsuru Yasuda, and Shin Ito, and Kenji Ito, and Shuichi Kawai, and Takamasa Yamaguchi, and Takashi Satoh, and Kenichi Sunaoshi, and Koichi Takeda, and Nobukazu Suzuki, and Shinichi Maeda, and Hirofumi Nishimura, and Souichirou Fukuda, and Tetsuro Matsumoto
Department of Urology, Sapporo Medical University School of Medicine, S1, W16, Chuo-ku, Sapporo, 0608543, Japan, stakahas@sapmed.ac.jp.

To clarify the clinical efficacy of STFX for patients with non-gonococcal urethritis (NGU), including chlamydial urethritis and Mycoplasma genitalium-positive urethritis, this study included male patients with NGU who were 20 years old or older. The pathogens, including Chlamydia trachomatis, M. genitalium and Ureaplasma urealyticum, were detected by nucleic acid amplification tests and the patients were treated with sitafloxacin 100 mg twice daily for 7 days. Microbiological and clinical efficacies were assessed for the patients with NGU posttreatment. Among the 208 patients enrolled in this study, data for a total of 118 patients could be analyzed. The median age was 32 (20-61) years. The median duration from the completion of treatment to the second visit was 21 (14-42) days. There were 68 pathogen-positive NGU cases and 50 with NGU without any microbial detection. Microbiological cure was achieved in 95.6% of the pathogen-positive NGU patients. Total clinical cure was achieved in 91.3% (105/115). In this study, STFX was able to eradicate 95.7% of C. trachomatis, 93.8% of M. genitalium and 100% of U. urealyticum. The results of our clinical research indicate that the STFX treatment regimen should become a standard regimen recommended for patients with NGU. In addition, this regimen is recommended for patients with M. genitalium-positive NGU.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D002692 Chlamydia trachomatis Type species of CHLAMYDIA causing a variety of ocular and urogenital diseases.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D014526 Urethritis Inflammation involving the URETHRA. Similar to CYSTITIS, clinical symptoms range from vague discomfort to painful urination (DYSURIA), urethral discharge, or both. Urethritides
D016905 Gram-Negative Bacterial Infections Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method. Bacterial Infections, Gram-Negative,Infections, Gram-Negative Bacterial,Bacterial Infection, Gram-Negative,Gram Negative Bacterial Infections,Gram-Negative Bacterial Infection,Infection, Gram-Negative Bacterial
D016990 Ureaplasma urealyticum A species of gram-negative bacteria found in the human genitourinary tract (UROGENITAL SYSTEM), oropharynx, and anal canal. Serovars 1, 3, 6, and 14 have been reclassed into a separate species UREAPLASMA parvum. Ureaplasma urealyticum biovar 2

Related Publications

Satoshi Takahashi, and Ryoichi Hamasuna, and Mitsuru Yasuda, and Shin Ito, and Kenji Ito, and Shuichi Kawai, and Takamasa Yamaguchi, and Takashi Satoh, and Kenichi Sunaoshi, and Koichi Takeda, and Nobukazu Suzuki, and Shinichi Maeda, and Hirofumi Nishimura, and Souichirou Fukuda, and Tetsuro Matsumoto
Clinical efficacy of levofloxacin 500 mg once daily for 7 days for patients with non-gonococcal urethritis.
June 2011, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy,
Satoshi Takahashi, and Ryoichi Hamasuna, and Mitsuru Yasuda, and Shin Ito, and Kenji Ito, and Shuichi Kawai, and Takamasa Yamaguchi, and Takashi Satoh, and Kenichi Sunaoshi, and Koichi Takeda, and Nobukazu Suzuki, and Shinichi Maeda, and Hirofumi Nishimura, and Souichirou Fukuda, and Tetsuro Matsumoto
Clinical and microbiological outcomes in treatment of men with non-gonococcal urethritis with a 100-mg twice-daily dose regimen of sitafloxacin.
June 2012, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy,
Satoshi Takahashi, and Ryoichi Hamasuna, and Mitsuru Yasuda, and Shin Ito, and Kenji Ito, and Shuichi Kawai, and Takamasa Yamaguchi, and Takashi Satoh, and Kenichi Sunaoshi, and Koichi Takeda, and Nobukazu Suzuki, and Shinichi Maeda, and Hirofumi Nishimura, and Souichirou Fukuda, and Tetsuro Matsumoto
Evaluation of ciprofloxacin 500 mg twice daily for one week in treating uncomplicated gonococcal chlamydial, and non-specific urethritis in men.
June 1986, Genitourinary medicine,
Satoshi Takahashi, and Ryoichi Hamasuna, and Mitsuru Yasuda, and Shin Ito, and Kenji Ito, and Shuichi Kawai, and Takamasa Yamaguchi, and Takashi Satoh, and Kenichi Sunaoshi, and Koichi Takeda, and Nobukazu Suzuki, and Shinichi Maeda, and Hirofumi Nishimura, and Souichirou Fukuda, and Tetsuro Matsumoto
The clinical efficacy of garenoxacin for male non-gonococcal urethritis.
April 2020, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy,
Satoshi Takahashi, and Ryoichi Hamasuna, and Mitsuru Yasuda, and Shin Ito, and Kenji Ito, and Shuichi Kawai, and Takamasa Yamaguchi, and Takashi Satoh, and Kenichi Sunaoshi, and Koichi Takeda, and Nobukazu Suzuki, and Shinichi Maeda, and Hirofumi Nishimura, and Souichirou Fukuda, and Tetsuro Matsumoto
Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients.
January 2003, AIDS (London, England),
Satoshi Takahashi, and Ryoichi Hamasuna, and Mitsuru Yasuda, and Shin Ito, and Kenji Ito, and Shuichi Kawai, and Takamasa Yamaguchi, and Takashi Satoh, and Kenichi Sunaoshi, and Koichi Takeda, and Nobukazu Suzuki, and Shinichi Maeda, and Hirofumi Nishimura, and Souichirou Fukuda, and Tetsuro Matsumoto
Efficacy of minocycline in single dose and at 100 mg twice daily for lepromatous leprosy.
December 1994, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association,
Satoshi Takahashi, and Ryoichi Hamasuna, and Mitsuru Yasuda, and Shin Ito, and Kenji Ito, and Shuichi Kawai, and Takamasa Yamaguchi, and Takashi Satoh, and Kenichi Sunaoshi, and Koichi Takeda, and Nobukazu Suzuki, and Shinichi Maeda, and Hirofumi Nishimura, and Souichirou Fukuda, and Tetsuro Matsumoto
Clinical Efficacy and Safety of Sitafloxacin 200 mg Once Daily for Refractory Genitourinary Tract Infections.
December 2021, Acta medica Okayama,
Satoshi Takahashi, and Ryoichi Hamasuna, and Mitsuru Yasuda, and Shin Ito, and Kenji Ito, and Shuichi Kawai, and Takamasa Yamaguchi, and Takashi Satoh, and Kenichi Sunaoshi, and Koichi Takeda, and Nobukazu Suzuki, and Shinichi Maeda, and Hirofumi Nishimura, and Souichirou Fukuda, and Tetsuro Matsumoto
[Efficacy of the dosing regimen of pantoprazole 40 mg, amoxicillin 1000 mg and clarithromycin 500 mg, twice daily for 7 days, in the eradication of Helicobacter pylori in patients with peptic ulcer].
January 2004, Arquivos de gastroenterologia,
Satoshi Takahashi, and Ryoichi Hamasuna, and Mitsuru Yasuda, and Shin Ito, and Kenji Ito, and Shuichi Kawai, and Takamasa Yamaguchi, and Takashi Satoh, and Kenichi Sunaoshi, and Koichi Takeda, and Nobukazu Suzuki, and Shinichi Maeda, and Hirofumi Nishimura, and Souichirou Fukuda, and Tetsuro Matsumoto
[Psychology of patients with non-gonococcal urethritis].
May 1957, Minerva dermatologica,
Satoshi Takahashi, and Ryoichi Hamasuna, and Mitsuru Yasuda, and Shin Ito, and Kenji Ito, and Shuichi Kawai, and Takamasa Yamaguchi, and Takashi Satoh, and Kenichi Sunaoshi, and Koichi Takeda, and Nobukazu Suzuki, and Shinichi Maeda, and Hirofumi Nishimura, and Souichirou Fukuda, and Tetsuro Matsumoto
Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily.
October 2004, The Journal of antimicrobial chemotherapy,
Copied contents to your clipboard!